NMS·Healthcare·$1.1B·#49 / 520 in Healthcare
XERS Xeris Biopharma Holdings, Inc.
71SOLID
CATEGORY BREAKDOWN
GROWTH70
QUALITY97
STABILITY67
VALUATION83
GOVERNANCE31
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+43.7%
70
> 50% strong
Gross Margin
Revenue retained after direct costs
85.4%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1885.4%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
3.7x
83
< 3x strong
Rule of 40
Growth rate plus operating margin
52
92
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.4%
27
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+10.6%
38
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE XERS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when XERS's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.